In a nutshell This study aimed to compare post-remission therapies for older patients with acute myeloid leukemia who are in complete remission. This study concluded that stem cell transplantation is more effective as a post-remission therapy than consolidation chemotherapy, but with more risks early-on. Some background...
Read MoreLeukemia Posts on Medivizor
Determining predictors of long-term survival in imatinib-treated chronic myeloid leukemia
In a nutshell This study aimed to determine potential predictors of long-term survival in patients with chronic myeloid leukemia (CML) treated with imatinib. This study concluded that phase at diagnosis and blood-cells response at 3 months were potential predictors of long-term survival in these patients. Some background Imatinib...
Read MoreLong term outcomes of imatinib treatment for chronic myeloid leukemia
In a nutshell This study aimed to investigate the long-term outcomes of imatinib treatment in patients with CML. This study concluded that imatinib is safe and effective for long periods of use. Some background Imatinib (Gleevec) is a tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia (CML). TKIs...
Read MoreLooking for patients to try a treatment combination for untreated chronic lymphocytic leukemia.
In a nutshell This study is searching for patients with previously untreated chronic lymphocytic leukemia (CLL) to try a new treatment combination containing obinutuzumab (Gazyva) or obinutuzumab/bendamustine (Treanda) to shrink the tumor (debulking) before treatment with venetoclax (Venclexta). The main outcome that will be measured is the number...
Read MoreEvaluating first-line imatinib for elderly patients with chronic myeloid leukemia
In a nutshell This study compared the effects of age and treatment dose for imatinib (Gleevec) in elderly versus younger patients with chronic myeloid leukemia (CML). This study concluded older patients had similar responses to therapy compared to younger patients. Some background Tyrosine kinase (TK) inhibitors are the standard therapy for chronic...
Read MoreEvaluating the risk of heart side effects of bosutinib in patients with chronic myeloid leukemia
In a nutshell This study evaluated the effects of bosutinib (Bosulif) on the heart in patients with chronic myeloid leukemia (CML). This study concluded that bosutinib was associated with heart-related side effects, particularly in high-risk patients. Some background Previous studies have shown that bosutinib is effective and well-tolerated. However,...
Read MoreEvaluating the heart side effects of anthracycline treatment in patients with AML undergoing stem cell transplantation
In a nutshell This study evaluated the side effects associated with anthracycline treatment in patients with acute myeloid leukemia (AML) who undergo stem cell transplantation (SCT). This study concluded that anthracycline treatment may impact survival outcomes for these patients after a SCT. Some background Cytarabine (Ara-C) plus an anthracycline...
Read MoreRituximab and idelalisib in the treatment of relapsed chronic lymphocytic leukemia
In a nutshell This study looked at the safety and effectiveness of rituximab (Rituxan) and idelalisib (Zydelig) in the treatment of relapsed chronic lymphocytic leukemia (CLL). The study found that idelalisib is safe and effective in these patients. Some background CLL is a cancer of the immune system. It is often treated with drugs that...
Read MoreStem cell transplant and TKI treatment in patients with chronic myeloid leukemia
In a nutshell This study looked at stem cell transplant and tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML). The study found that stem cell transplant is still an effective treatment in certain patients with CML. Some background CML is a cancer of the immune system. It may lead to abnormal immune cells. It is...
Read MoreDasatinib and chemotherapy vs stem cell transplant in the treatment of acute lymphoblastic leukemia
In a nutshell This study compared the outcomes after stem cell transplant (SCT) vs. dasatinib (Sprycel) combined with chemotherapy in the treatment of acute lymphoblastic leukemia (ALL) with abnormal genes. The study found that dasatinib and chemotherapy may be more effective in these patients. Some background ALL with...
Read MoreSearching for patients with lymphoma or leukemia to test T-cell therapy after stem cell transplantation
In a nutshell This phase 2 trial is evaluating how well CD8+ memory T-cell therapy works in patients with leukemia or lymphoma after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have full chimerism (donor cells work completely and only donor cells can be identified after transplant) after therapy. This...
Read MoreChemotherapy regimens for patients with relapsed or unresponsive acute myeloid leukemia
In a nutshell This study aimed to compare outcomes of fludarabine–treosulfan (FT), thiotepa–busulfan–fludarabine (TBF), and fludarabine, Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide (FLAMSA) in the treatment of patients with relapsed or unresponsive acute myeloid leukemia (AML). The study found that all...
Read More
